Cline Scientific has received communication that the European Patent Office (EPO) intends to grant the patent application related to the StemCART project. The patent application is titled “A method for providing a cartilage implant with chondrocytes”.
This notice of upcoming approval (Notice of Allowance) means that the EPO intends to grant the Company’s patent application. Once granted, which is anticipated late Q2 or early Q3, Cline can choose which of the 39 EPO member states in which to uphold the patent.
More about StemCART
StemCART is a preclinical Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide.
For more information check www.clinescientific.com